Epstein-Barr Virus Antibody to Viral Capsid Antigen, IgG and IgA

Also known as: EBV PAN 3

Clinical Use

Use

This test is used to support the detection and monitoring of Epstein-Barr virus (EBV) serological status by detecting antibodies to the viral capsid antigen. It is particularly helpful in assessing nasopharyngeal carcinoma risk. While it is not suitable for diagnosing infectious mononucleosis, it can provide valuable information in specific clinical scenarios involving EBV.

Special Instructions

Not provided.

Limitations

The test should not be used as a diagnostic tool for Epstein-Barr virus infectious mononucleosis. The performance characteristics of this test have not been cleared or approved by the US Food and Drug Administration. It is performed in a CLIA certified lab for clinical purposes but may have limitations in detection sensitivity and specificity based on the sample quality and patient's serological status.

Test Details

New York Approved

Methodology

Immunoassay (ELISA)

Biomarkers

EBV Antibody to Viral Capsid Antigen IgA

Antibody

Semi-Quantitative CLIA

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

EBV Antibody to Viral Capsid Antigen IgG

Antibody

Semi-Quantitative CLIA

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Order Codes

31369-2 - EBV VCA IgA Ser-aCnc
7885-7 - EBV VCA IgG Ser-aCnc

Result Codes

7885-7 - EBV VCA IgG Ser-aCnc
31369-2 - EBV VCA IgA Ser-aCnc

Result Turnaround Time

1-8 days

Specimen

Serum

Volume

2 mL

Minimum Volume

0.5 mL

Container

Serum separator tube (SST)

Collection Instructions

Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer serum to an ARUP standard transport tube.